Clinical Pharmacokinetics

, Volume 24, Issue 6, pp 435–440 | Cite as

Plasma Protein Binding and Pharmacological Response

  • Patrick du Souich
  • Josep Verges
  • Sergio Erill
Leading Article

Keywords

Furosemide Plasma Protein Binding Tolbutamide Free Fraction Basic Drug 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Belpaire FM, Bogaert MG, Mugabo P, Rosseel MT. Binding to serum alpha1 acid glycoprotein and effect of beta-adrenoceptor antagonists in rats with inflammation. British Journal of Pharmacology 88: 697–705, 1986PubMedCrossRefGoogle Scholar
  2. Boston Collaborative Drug Surveillance Program. Diphenylhydantoin side-effects and serum albumin levels. Clinical Pharmacology and Therapeutics 14: 529–532, 1973Google Scholar
  3. Branch RA, Roberts CJC, Homeida M, Levine D. Determinants of response to furosemide in normal subjects. British Journal of Clinical Pharmacology 4: 121–127, 1977PubMedCrossRefGoogle Scholar
  4. Brater DC. Resistance to diuretics: emphasis on a clinical perspective. Drugs 22: 477–494, 1981PubMedCrossRefGoogle Scholar
  5. Danhof M, Hisaoka M, Levy G. Kinetics of drug action in disease states: II. Effect of experimental renal disfunction on phenobarbital concentrations in rats at onset of loss of righting reflex. Journal of Pharmacology and Experimental Therapeutics 230: 627–631, 1984PubMedGoogle Scholar
  6. Du Souich P, Kobusch AB, Letarte L, Erill S. Pharmacokinetic basis of variability in drug response: a study of tolbutamide in models of disease. In Plaa et al. (Eds) Interactions between drugs and chemicals in industrial societies, pp. 1–25, Excerpta Medica, Amsterdam, 1987Google Scholar
  7. Greenblatt DJ, Allen MD. Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. British Journal of Clinical Pharmacology 5: 407–410, 1978PubMedCrossRefGoogle Scholar
  8. Greenblatt DJ, Koch-Weser J. Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: a report from the Boston Collaborative Drug Surveillance Program. European Journal of Clinical Pharmacology 7: 259–262, 1974PubMedCrossRefGoogle Scholar
  9. Gugler R, Azarnoff DL. Drug protein binding and the nephrotic syndrome. Clinical Pharmacokinetics 1: 25–35, 1976PubMedCrossRefGoogle Scholar
  10. Gugler R, Jensen JC. Drug-protein binding in liver disease and in patients with hypoalbuminemia. In Reidenberg & Erill (Eds) Drug-protein binding, pp. 188–200, Praeger Publishers, New York, 1986Google Scholar
  11. Halliday MJ, Dundee JW, Collier PS, Loughren PG, Harper KW. Influence of plasma proteins on the onset of hypnotic action of intravenous midazolam. Anaesthesia 40: 763–766, 1985PubMedCrossRefGoogle Scholar
  12. Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, et al. Mechanisms of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney International 32: 198–203, 1987PubMedCrossRefGoogle Scholar
  13. Levy G. Effect of plasma protein binding of drugs and intensity of pharmacological activity. Journal of Pharmaceutical Sciences 65: 1264–1265, 1976PubMedCrossRefGoogle Scholar
  14. Martinez-Jorda R, Aguirre C, Calvo R, Rodriguez-Sasiain JM, Erill S. Decrease in Penbutolol central response as caused by changes in its serum protein binding. Journal of Pharmacy and Pharmacology 42: 164–166, 1990PubMedCrossRefGoogle Scholar
  15. Odar-Cederlof I, Lunde PKM, Sjöqvist F. Abnormal pharmacokinetics of Phenytoin in a patient with uraemia. Lancet 2: 831–832, 1970PubMedCrossRefGoogle Scholar
  16. Paxton JW. Alpha1 acid glycoprotein and binding of basic drugs. Methods and Findings in Experimental and Clinical Pharmacology 5: 635–648, 1983PubMedGoogle Scholar
  17. Piafsky KM. Disease-induced changes in the plasma binding of basic drugs. Clinical Pharmacokinetics 5: 246–262, 1980PubMedCrossRefGoogle Scholar
  18. Sellers EM. Plasma protein binding displacement interactions are rarely of clinical significance. Pharmacology 18: 225–227, 1979PubMedCrossRefGoogle Scholar
  19. Shoeman DW, Azarnoff DL. Diphenylhydantoin potency and plasma protein binding. Journal of Pharmacology and Experimental Therapeutics 195: 84–86, 1975PubMedGoogle Scholar
  20. Sjöqvist F, Koike Y. Interindividual differences in drug-protein binding. In Reidenberg & Erill (Eds) Drug-protein binding, pp. 141–152, Praeger Publishers, New York, 1986Google Scholar
  21. Steinberg SF, Bilezikian JP. Total and free propranolol levels in sensitive and resistant patients. Clinical Pharmacology and Therapeutics 33: 163–171, 1983PubMedCrossRefGoogle Scholar
  22. Torres I, Gomez E, Garcia L, Suarez E, Rodriguez-Sasiain R, et al. Influence of changes in protein binding on the central activity of antidepressants. Journal of Pharmacy and Pharmacology 44: 531–533, 1992, 1992PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Patrick du Souich
    • 1
    • 2
  • Josep Verges
    • 1
    • 2
  • Sergio Erill
    • 1
    • 2
  1. 1.University of MontréalMontréalCanada
  2. 2.Esteve FoundationBarcelonaSpain

Personalised recommendations